Akturk HK, et al. - Researchers assessed the timing and issues connected with anti-programmed cell death protein-1 (PD-1)/anti-programmed cell death protein-1 ligand (PD-L1) inhibitor-induced type 1 diabetes. Out of 56 publications, a total of 71 cases were reviewed in this systematic review and meta-analysis. Within 3 months of initial PD-1/PD-L1 inhibitor exposure, many people developed type 1 diabetes. Compared to people without antibodies, those with type 1 diabetes-associated antibodies had a more rapid onset and a higher incidence of ketoacidosis. Clinicians who care for individuals receiving these state-of-the-art therapies must be aware of this potentially serious adverse event.